The branded division -- now Strativa -- launched its first product, Megace(R) ES, in July 2005. Megace ES (megestrol acetate) oral suspension is indicated for anorexia (loss of appetite), cachexia (severe malnutrition), and/or an unexplained, significant weight loss in patients with acquired immunodeficiency syndrome (AIDS). Megace ES generated more than $19 million in net sales in the second quarter of 2007. Megace ES sales are currently annualizing at over $75 million.
Strativa currently also has three Phase III in-licensed supportive care drugs in its pipeline:
-- Zensana(TM) (ondansetron HCl) (with Hana Biosciences, Inc) is being
studied for the prevention of nausea and vomiting after chemotherapy,
radiation and surgery. Following approval, Zensana is expected to be
the first anti-emetic therapy available in an oral spray form.
-- Loramyc(TM) (miconazole Lauriad(R)) (with BioAlliance Pharma) is an
antifungal therapy currently in Phase III development for the
treatment of oropharyngeal candidiasis, an opportunistic infection
commonly found in immunocompromised patients, including those with
cancer and HIV.
-- Pafuramidine maleate, (with Immtech Pharmaceuticals), also in Phase
III, is a novel anti-microbial drug being studied for the treatment of
pneumocystis pneumonia (PCP) in AIDS patients. Immtech and Strativa
may also collaborate to develop pafuramidine as a preventative therapy
for patients at risk of developing PCP, including those living with
HIV, cancer and other immunosuppressive conditions.
Important Safety Information
Some people may experience side effects associated with Megace ES that
|SOURCE Strativa Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved